Brief: Actinium Pharmaceuticals Highlights Improved Survival With Iomab-B In TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients In SIERRA Trial
23/02/2024 12:35
Feb 23 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM PHARMACEUTICALS INC - IMPROVED SURVIVAL WITH
IOMAB-B IN
TP53 POSITIVE RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA
PATIENTS IN SIERRA TRIAL
Source text for Eikon: ID:nPn9WW9dJa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities